The use of rifaximin in pre-operative period of patients with tumors of the gastrointestinal tract – a retrospective study (2013-2016)
| Autor: | Andrzej Mruk, Robert Sitarz, Ewa Maciąg, Robert Bakalarz, Jakub Litwiński, Nina Moroz, Ryszard Wierzbicki |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Colorectal cancer Preoperative care Rifaximin 03 medical and health sciences chemistry.chemical_compound Postoperative Complications 0302 clinical medicine Gastrointestinal Agents Preoperative Care Humans Medicine Outpatient clinic Gastrointestinal cancer Gastrointestinal Neoplasms Retrospective Studies Gastrointestinal agent business.industry General surgery Retrospective cohort study General Medicine Perioperative medicine.disease Rifamycins chemistry Elective Surgical Procedures 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Surgery Poland business |
| Zdroj: | Polish Journal of Surgery. 90:35-40 |
| ISSN: | 2299-2847 0032-373X |
| DOI: | 10.5604/01.3001.0011.5958 |
| Popis: | ntroduction: One of the most important goals of preparing a patient for elective gastrointestinal cancer surgery is prevention of postoperative complications. The literature gives many ways to prepare for surgery, but only a few suggests that pre-operative use of rifaximin provides benefits in the form of fewer perioperative complications and reduces the severity of pain during this period. O bjective: The presented project is a retrospective analysis of the effectiveness of rifaximin in the prevention of perioperative complications in patients treated in the Unit of General Surgery with the Orthopedic and Urology in the Hospital of the Ministry of the Interior and Administration in Lublin, and a review of international literature in this subject. Materials and methods: A retrospective analysis of the results of pre-operative use of rifaximin was performed in 181 patients scheduled for rectal and colorectal cancer between 2013 and 2016 in the General Surgery Unit with the Orthopedic and Urology in the Hospital of the Ministry of Interior and Administration in Lublin. Patients undergoing urgent surgery were excluded from the study. Patients were divided into 2 groups. The first group of 139 patients – patients operated on for rectal and colorectal cancer in 2013 until 2015, in whom rifaximine was not used in the preoperative period. The second group is 42 patients, operated on in 2016, in which the rifaximin was used in the pre-operative period at a dose of 2x2 tablets (400 mg) per day, 12-hour interval, for 7 days before the planned operation. Additionally, a probiotic was administered for 7 days. Drugs were ordained at the Oncological Outpatient Clinic as part of the pre-hospitalization check. R esults: The use of rifaximin in the preoperative period in patients with colorectal cancer had an effect on shortening the time of post-operative hospitalization and reduced post-surgical pain in comparison with the control group. The analysis of the cynumber and intensity of surgical complications in both groups did not differ. C onclusions: Large studies on the influence of rifaximin on the development of colorectal cancer have not been published so far. Only single reports suggest that its use has a positive effect on the perioperative period of patients treated for colorectal cancer including rectum and our retrospective analysis confirms these observations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|